Last reviewed · How we verify

Corticosteroids, Mycophenolate mofetil

Samsung Medical Center · Phase 1 active Small molecule ✓ Verified Jun 2026

Corticosteroids, Mycophenolate mofetil is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 1 development. Also known as: Methylon, CellCept.

Corticosteroids are used to treat conditions such as autoimmune uveitis, kidney transplant rejection, and graft rejection, as well as to suppress the immune system. Mycophenolate mofetil is not mentioned in the provided facts, but corticosteroids are part of the corticosteroid series, which is an intervention used in clinical trials.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCorticosteroids, Mycophenolate mofetil
Also known asMethylon, CellCept
SponsorSamsung Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Corticosteroids, Mycophenolate mofetil

What is Corticosteroids, Mycophenolate mofetil?

Corticosteroids, Mycophenolate mofetil is a Small molecule drug developed by Samsung Medical Center.

Who makes Corticosteroids, Mycophenolate mofetil?

Corticosteroids, Mycophenolate mofetil is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

Is Corticosteroids, Mycophenolate mofetil also known as anything else?

Corticosteroids, Mycophenolate mofetil is also known as Methylon, CellCept.

What development phase is Corticosteroids, Mycophenolate mofetil in?

Corticosteroids, Mycophenolate mofetil is in Phase 1.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing